Diagnostic Accuracy of MRI in Evaluating Response After Neoadjuvant Systemic Therapy in Operable Breast Cancer

被引:6
|
作者
Khazindar, Abdullah R. [1 ]
Hashem, Dalia Abdulmonem L. [2 ]
Abusanad, Atlal [3 ]
Bakhsh, Salwa, I [4 ]
Bin Mahfouz, Alya [5 ]
El-Diasty, Mohamed T. [5 ]
机构
[1] Univ Jeddah, Dept Radiol, Jeddah, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Diagnost Radiol, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Dept Pathol, Jeddah, Saudi Arabia
[5] King Abdulaziz Univ Hosp, Dept Radiol, Jeddah, Saudi Arabia
关键词
breast cancer; magnetic resonance imaging; complete pathological response; accuracy; radiological complete response; neoadjuvant chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY;
D O I
10.7759/cureus.15516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Neoadjuvant chemotherapy (NAC) is an important step in the treatment of various types of breast cancer by downsizing the tumor to make it operable. Determining disease extent after NAC is essential for accurate surgical planning. MRI has been the gold standard for detecting tumors that are usually difficult to detect on ultrasound or mammography. However, the use of MRI after NAC is controversial. Therefore, we aimed to evaluate the diagnostic accuracy of post-NAC MRI in the detection of residual disease preoperatively and to investigate the factors associated with pathological complete response (pCR). Methodology This retrospective review study was approved by the institutional review board with waiving of the informed consent. A total of 90 charts between January 2016 and January 2019 were reviewed. Baseline lesion size was measured as the maximal diameter in a single dimension by pretreatment MRI. To assess the diagnostic accuracy of MRI in detecting residual disease, we used two different definitions of pCR in the breast. The first is the resolution of both invasive disease and ductal carcinoma in situ. The second is the resolution of the invasive disease only. As a secondary objective of the study, we assessed the association between different patients' characteristics and both MRI and pathologic response using univariate and multivariate analysis. Results A total of 52 women (mean age: 47.4 years; range: 28-74) with 56 breast masses were eligible for the study. Complete MRI response was noted in 22 ( 39%) masses. pCR was achieved in 14 (25%) and 25 (44.6%) masses using the first and second pCR definitions, respectively. The negative predictive value (NPV) and overall accuracy of MRI for detecting residual disease were 50% and 75%, respectively, using the first pCR definition. With the second pCR definition, NPV and accuracy were 77.3% and 76.8%, respectively. Positive axillary lymph nodes were the only significant factor associated with incomplete MRI and pathological responses. Conclusions MRI NPV for residual disease was higher with the second pCR definition; however, overall accuracy was not different. MRI accuracy in detecting residual disease after NAC is not adequate to replace pathological assessment.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Metabolomic profiling and response to neoadjuvant therapy in operable breast cancer
    Gennari, A.
    Martini, V.
    Boldorini, R.
    Saggia, C.
    Rossi, V.
    D'Avanzo, F.
    Dodaro, I.
    Gallarotti, E.
    Rua, A.
    Branni, C.
    Stella, A.
    Tassone, A.
    Gioffi, E.
    Maggiora, P.
    Gambaro, A.
    Rampi, A.
    Sica, A.
    Khoso, S.
    Barberis, E.
    Manfredi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S132 - S132
  • [2] Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Locoregional and Systemic Therapy
    Bear, Harry D.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) : 607 - +
  • [3] Accuracy of multi-parametric breast MR imaging for predicting pathological complete response of operable breast cancer prior to neoadjuvant systemic therapy
    Tsukada, Hiroko
    Tsukada, Jitsuro
    Schrading, Simone
    Strobel, Kevin
    Okamoto, Takahiro
    Kuhl, Christiane K.
    MAGNETIC RESONANCE IMAGING, 2019, 62 : 242 - 248
  • [4] Diagnostic accuracy of contrast-enhanced mammography vs MRI in evaluating the response of breast cancer treated with neoadjuvant chemotherapy
    Lopez, Angela Iglesias
    Alejandro, Alberto Bouzon
    Lopez, Laura Abelairas
    Oses, Joaquin Jose Mosquera
    Romero, Jose Ramon Varela
    Chaves, Andres Vega
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2023, 36 (01):
  • [5] Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
    Mary Kathryn Abel
    Heather Greenwood
    Tatiana Kelil
    Ruby Guo
    Case Brabham
    Nola Hylton
    Jasmine Wong
    Michael Alvarado
    Cheryl Ewing
    Laura J. Esserman
    Judy C. Boughey
    Rita A. Mukhtar
    npj Breast Cancer, 7
  • [6] Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
    Abel, Mary Kathryn
    Greenwood, Heather
    Kelil, Tatiana
    Guo, Ruby
    Brabham, Case
    Hylton, Nola
    Wong, Jasmine
    Alvarado, Michael
    Ewing, Cheryl
    Esserman, Laura J.
    Boughey, Judy C.
    Mukhtar, Rita A.
    NPJ BREAST CANCER, 2021, 7 (01)
  • [7] Can MRI accurately identify which patients with operable breast cancer will have a pathologic complete response after neoadjuvant therapy?
    Nessim, Carolyn
    Trop, Isabelle
    Robidoux, Andre
    Mamounas, Eleftherios P.
    Boileau, Jean-Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Neoadjuvant Versus Adjuvant Systemic Therapy for Operable Breast Cancer Equivalent Outcomes?
    Smith, Barbara L.
    ANNALS OF SURGERY, 2013, 257 (02) : 180 - 181
  • [9] Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
    Bouzon, Alberto
    Acea, Benigno
    Soler, Rafaela
    Iglesias, Angela
    Santiago, Paz
    Mosquera, Joaquin
    Calvo, Lourdes
    Seoane-Pillado, Teresa
    Garcia, Alejandra
    RADIOLOGY AND ONCOLOGY, 2016, 50 (01) : 73 - 79
  • [10] Neoadjuvant therapy for operable breast-cancer
    Insa, A
    Chirivella, I
    Lluch, A
    MEDICINA CLINICA, 2006, 126 (08): : 295 - 303